These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
773 related articles for article (PubMed ID: 26623522)
1. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915 [TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population. Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971 [TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. Kim R; Keam B; Kwon D; Ock CY; Kim M; Kim TM; Kim HJ; Jeon YK; Park IK; Kang CH; Kim DW; Kim YT; Heo DS World J Gastroenterol; 2016 Oct; 22(37):8389-8397. PubMed ID: 27729745 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796 [TBL] [Abstract][Full Text] [Related]
6. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all? Hsu PK; Chien LI; Huang CS; Hsieh CC; Wu YC; Hsu WH; Chou TY Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):460-6. PubMed ID: 23728085 [TBL] [Abstract][Full Text] [Related]
7. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. Song Z; Yu X; Zhang Y Lung Cancer; 2016 Sep; 99():166-71. PubMed ID: 27565935 [TBL] [Abstract][Full Text] [Related]
8. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183 [TBL] [Abstract][Full Text] [Related]
9. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Fujimoto D; Uehara K; Sato Y; Sakanoue I; Ito M; Teraoka S; Nagata K; Nakagawa A; Kosaka Y; Otsuka K; Imai Y; Hamakawa H; Takahashi Y; Kokubo M; Tomii K Sci Rep; 2017 Sep; 7(1):11373. PubMed ID: 28900290 [TBL] [Abstract][Full Text] [Related]
10. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma. Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694 [TBL] [Abstract][Full Text] [Related]
11. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy. Chao YK; Chuang WY; Yeh CJ; Chang HK; Tseng CK Eur J Cardiothorac Surg; 2018 Jan; 53(1):201-208. PubMed ID: 28977486 [TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521 [TBL] [Abstract][Full Text] [Related]
13. Prediction of prognosis after trimodal therapy in patients with locally advanced squamous cell carcinoma of the oesophagus. Stahl M; Lehmann N; Walz MK; Stuschke M; Wilke H Eur J Cancer; 2012 Nov; 48(16):2977-82. PubMed ID: 22503151 [TBL] [Abstract][Full Text] [Related]
14. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease? Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905 [TBL] [Abstract][Full Text] [Related]
15. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170 [TBL] [Abstract][Full Text] [Related]
16. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy. Zhang F; Zhu X; Zhang Q; Zhou P; Hao L Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698 [TBL] [Abstract][Full Text] [Related]